Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder
Clinical trial NCT05512377 · COMPLETED
Trial details
- NCT number
- NCT05512377
- Sponsor
- Boehringer Ingelheim
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-12-13
- Primary completion
- 2025-09-25
- Enrollment
- 99
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.